20-F: Oncolytics Biotech Inc. Announces 2023 Financial Results and Provides Business Update

Oncolytics Biotech Inc. reports its 2023 financial results, highlighting ongoing clinical trials and strategic developments.

Summary

• Oncolytics Biotech Inc. reported a net loss of $27.8 million for the year ended December 31, 2023.
• The company's cash and cash equivalents totaled $34.9 million as of December 31, 2023.
• R&D expenses increased to $17.7 million in 2023 from $15.4 million in 2022.
• G&A expenses increased to $16.1 million in 2023 from $11.5 million in 2022.
• The company is focused on advancing its programs in HR+/HER2metastatic breast cancer and metastatic pancreatic ductal adenocarcinoma to registration-enabled clinical studies.
• Oncolytics is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
• The company received a US$5 million Therapeutic Accelerator Award from PanCAN to fund a Phase 1/2 pancreatic cancer study.
• The company has 150 issued patents, including 15 in the U.S. and 7 in Canada, with rights extending to at least the end of 2031.
• The company expects to increase its spending in connection with the research and development of pelareorep over the next several years.
• The company believes it has sufficient existing cash resources to fund its presently planned operations for at least the next twelve months from the balance sheet date.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company is making progress in its clinical trials and has secured funding, it is still operating at a loss and faces significant risks. The sentiment is neutral, reflecting the balance between positive developments and ongoing challenges.

Positives

• The company received a US$5 million Therapeutic Accelerator Award from PanCAN to fund a Phase 1/2 pancreatic cancer study.
• The company has 150 issued patents, including 15 in the U.S. and 7 in Canada, with rights extending to at least the end of 2031.
• The company believes it has sufficient existing cash resources to fund its presently planned operations for at least the next twelve months from the balance sheet date.

Negatives

• Oncolytics Biotech Inc. reported a net loss of $27.8 million for the year ended December 31, 2023.
• R&D expenses increased to $17.7 million in 2023.
• G&A expenses increased to $16.1 million in 2023.

Risks

• The company may not be able to raise additional funds through the sale of its common shares.
• The company expects to continue to incur substantial losses as it continues its research and development efforts.
• The company does not expect to generate significant revenues until and unless pelareorep becomes commercially viable.
• The company's success depends on the safety and efficacy of pelareorep, which is still in clinical trials.
• The company faces competition from other pharmaceutical and biotechnology companies.
• The company's operations could be adversely affected by events outside of its control, such as natural disasters, wars, or health epidemics.

Future Outlook

The company expects to increase its spending in connection with the research and development of pelareorep over the next several years as it looks to advance its breast and gastrointestinal cancer programs into later stages of clinical development. The company believes it has sufficient existing cash resources to fund its presently planned operations for at least the next twelve months from the balance sheet date.

Industry Context

The announcement highlights Oncolytics' focus on immuno-oncology, a rapidly evolving field in cancer treatment. The company's strategy of combining pelareorep with other therapies, such as checkpoint inhibitors and chemotherapy, reflects a broader industry trend towards combination therapies to improve treatment outcomes. The company faces competition from other companies developing cancer therapies, including those based on oncolytic viruses and other immunomodulatory approaches.

Comparison to Industry Standards

• The reported ORR of 62% and DCR of 85% in the first-line advanced/metastatic PDAC patients treated with the combination of pelareorep, atezolizumab and gemcitabine/nab-paclitaxel in the GOBLET platform study is substantially higher than the average ORR of ~25% reported in historical control trials of gemcitabine and nab-paclitaxel in metastatic pancreatic cancer.
• In a single-arm study of gemcitabine plus pelareorep, known as REO 017, first-line patients with metastatic pancreatic ductal adenocarcinoma, had a median OS of 10.2 months with 1-year and 2-year survival rates of 45% and 24%, respectively, compared to 20-22% and 25% benchmark 1-year and 2-year survivals, respectively, for metastatic PDAC patients treated with gemcitabine alone from two different phase 3 studies.
• Preliminary results from the anal carcinoma cohort of the GOBLET platform study showed ORR of 37.5% in second-line or later patients with squamous cell carcinoma of the anus treated with pelareorep plus atezolizumab, which compares favorably to the 10-14% ORRs reported in recent clinical trials of checkpoint inhibitor therapy is a similar second-line or later anal carcinoma populations.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for long-term value creation through successful drug development, but also risk of dilution and financial losses.
• Employees: Continued employment and potential for career growth, but also risk of job loss due to financial constraints or clinical trial failures.
• Patients: Potential access to new and effective cancer treatments, but also risk of side effects and limited efficacy.
• Collaborators: Opportunities for partnerships and revenue sharing, but also risk of disagreements and termination of agreements.
• Creditors: Risk of default on obligations if the company's financial condition deteriorates.

Next Steps

• Commencing a registration-enabled study in pancreatic cancer and introduce a new GOBLET cohort.
• Submitting a request for a Type C meeting with the FDA to seek guidance on our breast cancer program protocol design.
• Finalizing the breast cancer program registration pathway and commencing the relevant clinical study.
• Completing scaled-up cGMP production runs and the related batch testing.
• Initiating sourcing of a secondary fill/finish supplier.
• Filing for additional patents and monitoring activities required to protect our patent portfolio.

Key Dates

Keywords

Oncolytics Biotech, pelareorep, clinical trials, metastatic breast cancer, pancreatic cancer, financial results, immunotherapy, research and development, patents, biopharmaceutical